News

Home / News

TSH Biopharm acquires the commercialization right of all CellMax Life liquid-biopsy diagnosis products

2019.2.13 TSH Biopharm acquires the commercialization right of all CellMax Life liquid-biopsy diagnosis products

TSH Biopharm (8432) announced today to strategically invested in the US company CellMax Cayman and signed a distribution contract withits subsidary CellMax Life (hereafter referred to as CellMax Life) to acquire the exclusive commercialization right of all CellMax Life liquid- biopsy diagnosis products and subsequent new products in territory of Taiwan… View more